How does 688382's PB Ratio compare to its peers?

688382 is good value based on its Price-To-Book Ratio (3.8x) compared to the peer average (13.6x).

How does 688382's PB Ratio compare vs other companies in the CN Biotechs Industry?

688382 is expensive based on its Price-To-Book Ratio (3.8x) compared to the CN Biotechs industry average (2.2x).

What is 688382's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 688382's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of 688382 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

688382 (CN¥11.44) is trading above our estimate of [[fair value]] (CN¥7.56)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine [[statistical confidence]] in agreement.

688382 Stock Overview

A clinical stage biotech company, engages in the discovery and development of therapeutics for cancer and metabolic diseases in China and the United States. More details

688382 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 64.69% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months compared to the CN market

My Notes

Capture your thoughts, links and company narrative

InventisBio Co., Limited Competitors

Mabwell (Shanghai) Bioscience

SHSE:688062

CN¥8.5b

Shanghai MicuRx Pharmaceutical

SHSE:688373

CN¥3.3b

Dizal (Jiangsu) Pharmaceutical

SHSE:688192

CN¥17.5b

Frontier Biotechnologies

SHSE:688221

CN¥3.6b

Price History & Performance

Summary of share price highs, lows and changes for InventisBio
Historical stock prices
Current Share Price	CN¥11.44
52 Week High	CN¥15.49
52 Week Low	CN¥6.50
Beta	0.31
1 Month Change	16.02%
3 Month Change	44.99%
1 Year Change	-22.39%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-10.34%

Recent updates

Shareholder Returns

	688382	CN Biotechs	CN Market
7D	-8.9%	-1.9%	-1.0%
1Y	-22.4%	-19.6%	10.8%

Return vs Industry: 688382 underperformed the CN Biotechs industry which returned -18.4% over the past year.

Return vs Market: 688382 underperformed the CN Market which returned 12.3% over the past year.

Price Volatility

Is 688382's price volatile compared to industry and market?
688382 volatility
688382 Average Weekly Movement	11.9%
Biotechs Industry Average Movement	8.8%
Market Average Movement	8.8%
10% most volatile stocks in CN Market	13.0%
10% least volatile stocks in CN Market	5.8%

Stable Share Price: 688382's share price has been volatile over the past 3 months compared to the CN market.

Volatility Over Time: 688382's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of CN stocks.

About the Company

Founded	Employees	CEO	Website
2013	188	Yaolin Wang	www.inventisbio.com

InventisBio Co., Limited, a clinical stage biotech company, engages in the discovery and development of therapeutics for cancer and metabolic diseases in China and the United States. The company’s drug candidates for the oncology therapeutic area include BPI-D0316, which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; D-0502, which is in Phase I clinical trial for the breast cancer indications; and D-1553, which in Phase I clinical trial for NSCLS, colorectal cancer indications. Its drug candidates for the metabolic therapeutic area is D-0120, a Phase I and II clinical trial product for hyperuricemia and gout indications.

InventisBio Co., Limited Fundamentals Summary

How do InventisBio's earnings and revenue compare to its market cap?
688382 fundamental statistics
Market cap	CN¥6.60b
Earnings (TTM)	-CN¥348.02m
Revenue (TTM)	CN¥77.51m

85.1x

P/S Ratio

-19.0x

P/E Ratio

Is 688382 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
688382 income statement (TTM)
Revenue	CN¥77.51m
Cost of Revenue	CN¥7.03m
Gross Profit	CN¥70.48m
Other Expenses	CN¥418.50m
Earnings	-CN¥348.02m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.60
Gross Margin	90.93%
Net Profit Margin	-448.98%
Debt/Equity Ratio	0%

How did 688382 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/25 14:57
End of Day Share Price	2024/12/25 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

InventisBio Co., Limited is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ziyu He	China International Capital Corporation Limited
Xiaoyi Qu	China International Capital Corporation Limited
Tan Huan Gan	Citic Securities Co., Ltd.